Skip to main
CSTL

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. is experiencing significant growth in its TissueCypher test, with test volume increasing by 92% year-over-year and 23% quarter-over-quarter in the second quarter of 2025, driven by an expanded sales force. The company has also improved the gross margin for the TissueCypher product, achieving an impressive 77% in the most recent quarter, which is anticipated to be supported by a mature gastrointestinal sales force in the second half of 2025. Overall, the strong performance and growth trajectory of the TissueCypher test, along with its industry-leading gross margins, contribute to a positive outlook for Castle Biosciences's stock.

Bears say

Castle Biosciences Inc faces challenges regarding its projected revenue multiples for its dermatology and DecisionDx-UM tests, particularly due to the anticipated lower valuation compared to TissueCypher. The company’s management acknowledged a lack of clinician awareness, especially among gastroenterologists, which could hinder the adoption of their tests, reinforcing concerns about penetration rates in key markets. Despite indications that the stock may appear undervalued based on conservative estimates, the underlying issues related to market awareness and adoption present a negative outlook for future growth and revenue generation.

CSTL has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Strong Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Strong Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.